Idexx Laboratories: Recurring Diagnostics Strength, Innovation Pipeline, and Pet Health Tailwinds Support Buy Rating

William Blair analyst Ryan Daniels has maintained their bullish stance on IDXX stock, giving a Buy rating on January 16.

Ryan Daniels has given his Buy rating due to a combination of factors that underscore Idexx Laboratories’ strong operating performance and favorable outlook. The company delivered fourth-quarter 2025 revenue and earnings that surpassed market expectations, driven in part by double‑digit growth in high‑margin, recurring diagnostics revenue within its core companion animal business. In addition, management’s initial 2026 guidance called for solid top‑line expansion and earnings per share above consensus, reinforcing confidence in the sustainability of growth.

Daniels also points to Idexx’s robust innovation pipeline—particularly the new cancer diagnostics and InVue Dx offerings—as a key driver that can offset macro headwinds such as softer veterinary visit trends. He believes this innovation cycle, together with recurring revenue strength, gives the company meaningful levers to execute in a challenging environment. Furthermore, structural tailwinds in pet health, including an aging post‑2020 pet cohort and higher spending tendencies among younger pet owners, support a durable demand backdrop. Taken together, these operational, strategic, and secular factors justify his positive view and underpin the Buy recommendation on IDXX shares.

In another report released on January 16, TipRanks – Google also reiterated a Buy rating on the stock with a $813.00 price target.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IDXX in relation to earlier this year.